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Object. Previous reports suggest that adjustable valves may improve the survival of cerebrospinal fluid shunts or 
relieve shunt-related symptoms. To evaluate these claims, the authors conducted a prospective multicenter cohort 
study of children who underwent placement of Strata valves.
Methods. Patients undergoing initial shunt placement (Group 1) or shunt revision (Group 2) were treated using 
Strata valve shunt systems. Valves were adjustable to five performance level settings by using an externally applied 
magnet. The performance levels were checked using an externally applied hand tool and radiography. Patients were 
followed for 1 year or until they underwent shunt revision surgery.
Between March 2000 and February 2002, 315 patients were enrolled in the study. In Group 1 (201 patients) the 
common causes of hydrocephalus were myelomeningocele (16%), aqueductal stenosis (14%), and hemorrhage (14%). 
The overall 1-year shunt survival was 67%. Causes of shunt failure were obstruction (17%), overdrainage (1.5%), loc­
ulated ventricles (2%), and infection (10.6%)- Patients in Group 2 (114 patients) were older and the causes of hydro­
cephalus were similar. Among patients in Group 2 the 1-year shunt survival was 71%.
There were 256 valve adjustments. Symptoms completely resolved (26%) or improved (37%) after 63% of adjust­
ments. When symptoms improved or resolved, they did so within 24 hours in 89% of adjustments. Hand-tool and ra­
diographic readings of valve settings were the same in 234 (98%) of 238 assessments.
Conclusions. The 1-year shunt survival for the Strata valve shunt system when used in initial shunt insertion pro­
cedures or shunt revisions was similar to those demonstrated for other valves. Symptom relief or improvement fol­
lowing adjustment was observed in 63% of patients. Hand-tool assessment of performance level settings reliably 
predicted radiographic assessments.
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I n pediatric patients, hydrocephalus is most commonly managed with VP shunt placement. To reduce the fail­ure rate of these mechanical devices, recent investiga­
tors have been focused on valves that are incorporated into 
the VP shunt system . 1 - 5'7-9 Researchers have not yet iden­
tified a valve that is clearly superior to the other available 
devices when used in a broad range of children with hy­
drocephalus.
Valves are currently available with a wide variety of 
pressure flow characteristics. In the past, a surgical proce­
dure was required to change a valve setting; recently, valves 
that are externally adjustable with the aid of a magnet have 
become available. In theory, the use of these devices could 
decrease the frequency of shunt revision. Clinical experi­
ence with the Codman Hakim programmable valve (Rayn- 
ham, MA) has been reported in an uncontrolled series of 
583 patients (children and adults).8-9 The authors reported a
Abbreviations used in this paper: CI = confidence interval; 
IVH = intraventricular hemorrhage; SDT = Shunt Design Trial; 
VP = ventriculoperitoneal.
5-year shunt survival of 53% and a low (2%) incidence of 
valve malfunction among patients undergoing initial shunt 
placement. The findings of a randomized trial comparing 
the Codman Hakim programmable valve with differential 
pressure valves demonstrated that the safety and efficacy of 
the Codman Hakim programmable valve is comparable to 
that of conventional valves.5
Despite the current interest in the adjustability feature of 
the Codman Hakim programmable valve, the absence of a 
flow- or siphon-control mechanism was a concern. In the 
current study we assessed a new adjustable valve. The Stra­
ta valve (Medtronic Neurosurgery, Goleta, CA) allows for 
noninvasive adjustment to different pressure flow profiles, 
referred to as performance level settings. The Strata valve 
also includes a siphon-control mechanism and allows for 
evaluation of the performance level setting without the use 
of radiography. To assess the performance of the new valve 
in children with hydrocephalus, a prospective multicenter 
cohort study was conducted. The objective of the study was 
to determine the safety and efficacy of the Strata valve and 
to compare it with the performance of currently accepted 
nonadjustable valves.
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Fig. 1. Chart indicating the enrollment criteria for Groups 1 
(Core) and 2 (Adjunct).
Clinical M aterial and M ethods
Patient Population
This study was a nonrandomized prospective cohort 
study in which all patients underwent placement of a Strata 
valve. There were two study populations: Group 1, in which 
patients underwent insertion of their first VP shunt, and 
Group 2, in which patients underwent shunt revision. The 
entry criteria for the two groups are outlined in Fig. 1. In 
Group 1, the entry criteria were intentionally designed to be 
similar to the entry criteria in the SDT;1 this was done to 
make the patient population similar to that of the SDT and 
to strengthen the comparison of the results.
Surgical Procedures
The primary study end point was shunt revision surgery. 
This was defined in four categories: obstruction, overdrain­
age, loculated compartments, or infection. These definitions 
are the same as those used in previous hydrocephalus trials, 
including the SDT and the Endoscopic Shunt Insertion Tri­
al.13 This was done to strenghten the comparison between 
the current study and the historical literature.
In all of the surgeries (shunt insertion or revision), the 
Strata valve was placed; other flow-control devices were 
not allowed. The choice of ventricular and/or peritoneal tub­
ing, the surgical technique of insertion, and the details of pe­
rioperative care were determined by the individual surgeon. 
The protocol suggested that the initial performance level of 
the Strata valve should be 1.0; however, if the surgeon de­
termined that a different initial performance level was re­
quired, this was allowed.
Data Collection
Data (including symptoms and severity) were collected 
at baseline; discharge; and at 1, 3, 6 , and 12 months post­
operatively, and at any other time that was clinically indi­
cated. If a patient underwent follow-up examination and 
the valve was adjusted, symptoms were reassessed within 
24 hours. Any valve adjustments were followed by skull 
radiography. The performance level setting obtained from 
the skull radiograph was compared with the performance 
level setting that was obtained at the bedside with the use 
of the hand-held tool. Patients who presented with either
loculated compartments in the ventricular system or infec­
tion did not undergo valve adjustment; they were treated 
according to the surgeon’s usual practice. Patients who 
presented with shunt obstruction or overdrainage were eli­
gible for adjustment. The protocol allowed up to three ad­
justments within a 72-hour period, as long as symptoms 
were improving. If symptoms were persistent or progres­
sive despite these adjustments, revision was recommend­
ed in accordance with the surgeon’s usual practice.
Sample Size
The study was designed to generate a 1-year shunt sur­
vival for the Strata valve with a 95% CI. To make a com­
parison to the SDT, the shunt survival from that study was 
used in calculating our sample size. In the SDT, the overall 
1 -year shunt survival was 61%, and the lower limit of the 
95% CI was 51%. Because the valves in the SDT are all 
commonly used in current clinical practice, we chose the 
SDT result (a lower limit of the 95% CI equal to 51%) as 
our minimum acceptable 1-year shunt survival. We calcu­
lated a sample size for the Strata valve that would have a CI 
with a lower limit of 51% or greater. Using these parame­
ters, a power of 80% and alpha of 0.05, we determined that 
152 patients needed to be evaluated in Group land fol­
lowed for a minimum of 1 year.
Patients undergoing shunt revision (Group 2) were en­
rolled in the study to generate additional outcome data. 
There was no specific hypothesis proposed or tested with 
regard to these patients and, therefore, a specific sample 
size was not calculated.
Individual participating institutions submitted propos­
als to the appropriate institutional review board and joined 
the study once approval was obtained. The valve had not 
yet been approved by the Food and Drug Administration 
at the beginning of the study but was approved on Febru­
ary 1 1 , 2 0 0 2 , based on an interim data report provided 
by the manufacturer. Data collection and site monitoring 
were performed by Medtronic, Inc.; data analysis and in­
terpretation were performed by the authors.
Results
Patient accrual began in March 2000 and closed at the 
end of February 2002. The follow-up phase closed at the 
end of February 2003. Three hundred fifteen patients were 
enrolled—201 in Group 1 and 114 in Group 2.
As expected, in view of the entry criteria, the baseline 
characteristics of the patients in Group 1 of this study were 
similar to those in the SDT (Table 1). The patients were in­
fants (median age 0.41 years) at the time of shunt place­
ment. A little more than half were boys, and the median 
birth weight was 3026 g. As expected for such a young pop­
ulation, the most common causes of hydrocephalus were 
myelomeningocele, aqueductal stenosis, brain tumor, and 
IVH. Shunts were inserted via a frontal approach in 87 
cases and via a posterior/parietal approach in 103 patients. 
Some form of assistance during insertion of the ventricular 
catheter (endoscopy, ultrasonography, or other imaging) 
was used in 21% of patients. Perioperative antibiotic agents 
were used in all patients in Group 1. The median time from 
study registration to hospital discharge, was 2  days, and the 
median surgical time was 40 minutes. The overall 1-year
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TABLE 1
Summary o f the baseline characteristics o f patients in 
Group 1 compared with those from the SDT
Characteristics Group 1 SDT
no. of patients 201 344
median age (yrs) 0.41 0.22
sex (% M/F) 57/43 56/44
birth weight (g) 3026 2825
cause of hydro­ myelomeningo­ myelomeningo­
cephalus cele, aqueduc- cele, IVH, tu­
tal stenosis, mor, aqueduc-
tumor, IVH tal stenosis
shunt survival was 67% (95% CI 60-74%; Fig. 2). The 
most common cause of shunt failure was obstruction, which 
occurred in 17% of patients. Overdrainage occurred in 
1.5% of patients, loculation in 2%, and infection in 10.6%.
In Group 2 patients the median age was 8.7 years. The 
1-year shunt survival was 71% (95% CI 62-80%; Fig. 3). 
In these patients, obstruction was the most common cause 
of failure, occurring in 20% of patients. Overdrainage oc­
curred in 3.7%. No patient developed loculated compart­
ments within the ventricular system, and the infection rate 
was 6%.
After valve implantation, the initial performance level 
setting in Group 1 was most commonly 1 or 1.5 (30 and 
40%, respectively). In Group 2 patients, 1.5 and 2 were 
the most common initial performance level settings (56 
and 23%, respectively; Table 2).
A total of 256 valve adjustments were made in 141 pa­
tients. In Group 1, 92 (46%) of 201 patients underwent 
valve adjustment. Fifty-five of these patients underwent 
single adjustments and 37 underwent multiple adjustments. 
In Group 2, 49 (43%) of 114 patients underwent valve ad­
justment. In 24 patients a single adjustment was performed, 
and in 25 patients multiple adjustments were required. Of 
the 256 valve adjustments the reason for the valve adjust­
ment was shunt obstruction in 23 and overdrainage in 59. 
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F ig . 2. Graph. The 1-year shunt survival rate (time to first shunt 
failure) in the 201 patients in Group 1 was 67%.
.3
0.0 __________________ s__________________=__________________ =___________________
0.0 .5 1.0 1.5  2.0
Time (years)
F ig . 3. Graph. The 1-year shunt survival rate (time to first shunt 
failure) in the 114 patients in Group 2 was 71%.
tion did not meet the definition of obstruction or overdrain­
age; the most common reason was headache.
After valve adjustments were performed, patients and/or 
families reported symptoms as completely resolved, im­
proved (but not resolved), the same, or worse. Follow-up 
information was available after 236 of the 256 adjustments. 
Overall, symptom improvement or resolution occurred in 
149 (63%) of 236 adjustments. In 61 instances (26%), com­
plete symptom resolution occurred, and in 87 (37%) of 236 
instances, symptoms were improved but not resolved. The 
improvement or resolution of symptoms occurred within
24 hours in 132 (89%) of 149 occasions. The 1-year survi­
val rate for adjusted valves was the same as that for valves 
which were not adjusted (Fig. 4).
During the study, radiographic confirmation of the per­
formance level setting was obtained after 238 valve adjust­
ments. These readings were compared with the hand-held 
instruments that were used at the bedside to evaluate the 
performance level setting. The agreement between these 
two methods was very good; the same reading was ob­
tained in 234 of 238 instances. There were four discrepan­
cies observed between the radiographic and the hand-held 
tool performance level settings: 0.5 compared with 1; 1 
compared with 0.5; 1.5 compared with 0.5; and 2 compared 
with 2.5, respectively.
Surgeons were asked to report surgery- and device-re­
lated complications that occurred during the implant. No 
such complications were reported in Group 2. In Group 1, 
there were two surgery-related complications listed as 
“small cortical bleeding stopped with coagulation” and 
“cerebrospinal fluid tracking up the peritoneal end.” In 
Group 1 there were also two device-related complications 
recorded as “valve too big for neonate” and “tear in dome 
on imaging, second valve implanted.” One surgeon re­
ported “brief bradycardia without consequences” in the 
device- and surgery-related categories.
There was one death in the study, which was due to pro­
gression of Hurler syndrome and not related to shunt mal­
function.
An unexplained change in the performance level oc­
curred 25 times among 22 patients treated in eight investi-
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Summary o f initial settings for patients in 
Groups 1 and 2 *
TABLE 2






*PL = perform ance level.
gational sites. Seventeen of these patients were asymptom­
atic and five experienced symptoms (headache, irritability, 
and lethargy in two; and hemiparesis, seizures, and slit ven­
tricles in one each). Three of the five symptomatic patients 
had their valves reset, as did seven asymptomatic patients. 
There were 12 asymptomatic patients in whom valves were 
not reset.
Discussion
In hopes of reducing the failure rate of VP shunts for 
hydrocephalus in pediatric patients, considerable research 
has been focused on valves. Adjustable valves that allow 
noninvasive changes to be made in the pressure flow char­
acteristics have recently become available. Theoretically, 
these devices offer potential advantages such as improved 
shunt survival and the ability to change ventricular size 
and/or relieve symptoms.
In this study, the Strata valve was evaluated in a prospec­
tive cohort of children, some of whom underwent initial 
shunt placement and some of whom underwent implan­
tation of the new valve at the time of shunt revision. The 1- 
year shunt survival of the Strata valve when used at the 
time of initial shunt insertion was 67% (95% CI 60-74%), 
a rate similar to that for a number of other valves that are 
currently on the market. The strongest comparison from 
historical data is to the SDT1 because the entry and out­
come criteria in the two studies were similar. The shunt sur­
vival curve for the Strata valve and the point estimates of 
the 1-year shunt survival for the valves in the SDT are dem­
onstrated in Fig. 5. The 1-year survival was 67% for the 
Strata valve, 66% for the Sigma valve, 61% in the standard 
group (differential pressure valves), and 56% for the Delta 
valve. The 95% CIs for the Strata valve and the three valves 
in the SDT overlap, implying that the failure rates are sim­
ilar. Our study design does not provide convincing evi­
dence that the Strata valve has a survival advantage; a ran­
domized trial would be required to test this hypothesis.
There has only been one previous study in which direct 
comparison of adjustable and nonadjustable valves is re­
ported.5 In a randomized trial the Codman Hakim pro­
grammable valve was compared with differential pressure 
valves in a mixed group of patients which included adults 
and children undergoing shunt revision and shunt insertion. 
The shunt survival rate curves in those two groups were 
virtually identical, and both curves were similar to the re­
sults of the current study.
The literature that is provided with the Strata valve and 
our study protocol suggested that the valve be implanted in 
the coronal position. If the valve is implanted below the 
midposition of the ventricle, there is a concern that it may 
remain open and lead to overdrainage. In this study, the 
majority of valves (103 of 201 in Group 1) were implanted 
using a posterior parietal approach; therefore, the valve 
might have been below the midposition of the ventricle in 
some or all of those patients. Regardless, overdrainage was 
rare (1.5%). In the SDT the incidence of overdrainage was 
7.8% with the Delta valve, 2.6% with the standard (differ­
ential pressure) valve and 0% with the Sigma valve. It is 
difficult to evaluate the importance of valve position based 
on the findings of these two studies because overdrainage 
is a late complication and the follow-up period was much 
longer in the SDT than in our study.
Repeated studies with different valves, both adjustable 
and nonadjustable, and with and without siphon control 
mechanisms, have demonstrated similar 1 -year shunt sur­
vival in the 60 to 70% range.1-6-8-9 It appears that there is no 
single best valve to treat all forms of hydrocephalus in pedi-
Time (years)
F ig . 4. Graph indicating the time to first shunt failure for shunts 
that were and were not adjusted.
Time (years)
F ig . 5. Graph indicating the survival rates of the Strata valve 
and other (nonadjustable) valves from the SDT.
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atric patients. Individualized valve choice based on age, 
ventricle size, and perhaps other factors may be important.
The potential advantages of adjustable valves may not 
yet be realized. One potential advantage might be the abil­
ity to reduce the size of ventricles slowly and/or to maintain 
a larger ventricle size than that obtained with nonadjustable 
valves; this was not part of the protocol for the current 
study Although such an approach has yet to be assessed 
formally, it is currently being attempted by some surgeons.
The majority of patients who presented with symptoms 
resulting in valve adjustment did not meet the criteria for 
study end point (obstruction or overdrainage). Valve adjust­
ment was associated with improvement in symptoms al­
most two thirds (63%) of the time. When improvement or 
resolution of symptoms occurred it did so within 24 hours 
in the vast majority of patients. In view of such rapid im­
provement in symptoms, it appears likely that a surgeon 
will know fairly quickly whether valve adjustment will be 
beneficial. Because the majority of symptoms were subjec­
tive in nature (headaches), and the symptom scoring was 
self-reported, the possibility of a placebo effect exists. Pla­
cebo valve adjustments were not performed in this study
Conclusions
The 1 -year shunt survival for the Strata valve was sim­
ilar to the survival demonstrated for other valves. Valve 
adjustments resulted in symptom relief or improvement in 
more than half of the patients. The correlation between the 
hand-held device for checking the performance level set­
ting and the radiographs was very good. It is our belief 
that the hand-held device obviates the need for radiogra­
phy, except in circumstances that might be indicated clin­
ically, such as lack of symptom improvement.
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Murphey Clinic, Memphis, Tennessee.
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J. Duncan. Rhode Island Hospital, Providence, Rhode Island.
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Charleston, South Carolina.
J. Jane Sr.. J. Jane Jr.. N. Kassel. University o f Virginia, Char­
lottesville, Virginia.
D. Jimenez. University o f Missouri-C.olumbia, Columbia, Mis­
souri.
M. Levy. G. McComb. M. Krieger. Children's Hospital o f I  ms 
Angeles, Ix>s Angeles, California.
J. Madsen. M. Proctor. R. M. Scott. Boston Children's Hospital, 
Boston, Massachusettes.
M. Muhonen. W. Louden. C. Green. Children's Hospital of 
Orange County, Orange, California.
M. Nagib. Minneapolis Children's Hospital, Minneapolis, Min­
nesota.
J. Pattisapu. E. Trumble. C. Gegg. Arnold Palmer Children's 
Hospital, Orlando, Florida.
J. Ragheb. G. Morrison. University o f Miami Children's Hospi­
tal, Miami, Florida.
H. Rekate. B. Cherny. Barrow Neurological Institute, Phoenix, 
Arizona.
J. Ward. Virginia Commonwealth University, Richmond, Virginia.
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